证券之星消息，2025年11月14日吉贝尔（688566）发布公告称公司于2025年11月14日召开业绩说明会。 具体内容如下： 问：（1）公司的销售差异化这么大，有什么策略升其他区域的销售额？（2）尼群洛尔片效果这么好，有 什么销售策略打开市场？（3）公司上市五年了营收没有比较大的改变，特别是各个地区销售不平衡，如 果华南、华中地区的销售做到华东地区的80%，公司总体营收和利润都起来了。（4）公司有没有出海的 计划？ 答：目前，公司新工厂充分考虑未来市场需求，整体智能化水平较高，产能覆盖公司现有产品及在研产 品，有效满足公司业务发展需要。 答：从全国范围来看，公司产品存在销售区域发展不均衡，仍然有较大的空白市场。公司制定相关政策， 树立标杆，对标找差，完善竞争和激励机制，优化资源配置，进一步加强空白市场开发力度，挖掘增量市 场空间。 尼群洛尔片是国内首个一类复方抗高血压新药，在高血压伴高心率细分领域具体领先优势。近 年来，公司通过组建专门事业部、构建专家网络，加快推进尼群洛尔片在高血压伴高心率细分领域的推广 与运用，产品销售收入实现了持续较快增长。截至2025年9月底，尼群洛尔片覆盖医院总数7,000余家， ...

Core Insights - The company reported a stable revenue growth of 4.14% year-on-year, achieving a total revenue of 897 million yuan in 2024, with a net profit of 219 million yuan, reflecting a slight increase of 0.11% [1] - The company continues to prioritize shareholder returns, proposing a cash dividend of 2.6 yuan per 10 shares, indicating confidence in future growth [1][7] - The company aims for sustainable growth in 2025 through a "quality improvement and efficiency enhancement" action plan, focusing on core business optimization, R&D innovation, and efficiency improvements [1][6] Financial Performance - In 2024, the company generated a net cash flow from operating activities of 215 million yuan, marking a significant increase of 34.98% [1] - The core product, Likujun tablets, contributed approximately 652 million yuan to revenue, accounting for 72.7% of total revenue [2] - The second core product, Niqunluo tablets, saw a revenue increase of 41.46% year-on-year, reaching 127 million yuan [2] Operational Efficiency - The company reduced its total employee count by 8.17% to 1,327, while increasing revenue per employee by 13.4% to approximately 675,600 yuan [3] - Accounts receivable decreased by 18.53%, indicating improved cash flow management [3] R&D Investment - The company invested 70.41 million yuan in R&D in 2024, an increase of 26.25% year-on-year [4] - The company is advancing multiple new drug candidates, including JJH201501 for depression and JJH201601 for cancer, with ongoing clinical trials [4][5] Future Strategy - The company plans to enhance its core product market positions and expand its sales scale in 2025, focusing on the promotion of Likujun tablets and Niqunluo tablets [6] - The company aims to improve operational efficiency through refined management practices and resource optimization [6] - The company has a history of consistent cash dividends, with a total of 1.55 billion yuan in dividends proposed for 2024, representing 70.58% of net profit [7][8]